Last update 28 Mar 2025

Prednisolone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione, 1,4-pregnadiene-11β,17α,21-triol-3,20-dione, 1,4-pregnadiene-3,20-dione-11β,17α,21-triol
+ [20]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (21 Jun 1955),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H28O5
InChIKeyOIGNJSKKLXVSLS-VWUMJDOOSA-N
CAS Registry50-24-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mucocutaneous Lymph Node Syndrome
Japan
13 Sep 2013
Mucocutaneous Lymph Node Syndrome
Japan
13 Sep 2013
Multiple Myeloma
Japan
16 Sep 2011
Multiple Myeloma
Japan
16 Sep 2011
Preeclamptic Toxemia
Japan
23 Jul 1985
Eczema
Japan
01 Jul 1967
Adrenal Insufficiency
United States
21 Jun 1955
Arthritis
United States
21 Jun 1955
Autoimmune Diseases
United States
21 Jun 1955
Celiac Disease
United States
21 Jun 1955
Colitis, Ulcerative
United States
21 Jun 1955
Insulin Resistance
United States
21 Jun 1955
Leukemia
United States
21 Jun 1955
Lymphoma
United States
21 Jun 1955
Systemic Lupus Erythematosus
United States
21 Jun 1955
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rhinitis, AllergicPhase 3-01 Nov 2013
Plasma Cell LeukemiaPhase 3
United States
13 Jan 2012
Plasma Cell LeukemiaPhase 3
China
13 Jan 2012
Plasma Cell LeukemiaPhase 3
Australia
13 Jan 2012
Advanced Prostate CarcinomaPhase 2
South Korea
30 Aug 2011
Advanced Prostate CarcinomaPhase 2
Taiwan Province
30 Aug 2011
Rheumatoid ArthritisPhase 2
Australia
21 Jun 2005
Rheumatoid ArthritisPhase 2
France
21 Jun 2005
Rheumatoid ArthritisPhase 2
Germany
21 Jun 2005
Rheumatoid ArthritisPhase 2
Russia
21 Jun 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Oral prednisone 60mg/day
baqwdvtmwt(mryaxmowkk) = tbtszezrop mbgmlwtvnd (btshddzuih )
-
13 Oct 2024
baqwdvtmwt(mryaxmowkk) = otfiiyelfc mbgmlwtvnd (btshddzuih )
Not Applicable
153
High-dose glucocorticoids (≥ 30 mg/day)
wwwdkmzrom(iugccwddpm) = huqrjiuwnp qvkqjmepgv (bwzahnxkjf, 8.9 - 12.3)
Positive
05 Jun 2024
Not Applicable
121
Glucocorticoids
njxmvdqere(nrgdwctcdr) = trpwglwios xldrxbaheo (xgjlgcxgjq )
Positive
05 Jun 2024
Immunosuppressive agents (ISA)
ogotmaokkk(ntoljovahv) = sqemuxmhef daggfwckdh (jawcqntpzw )
Phase 4
48
cswrkmecja(utpzdhnbbf) = fhahmqlzab apzgsfeydr (jywwcwqzfd )
Positive
05 Apr 2024
Phase 2
54
R-CHOP regimen + IT liposomal cytarabinmethotrexatedose methotrexate
roviagpheu(wwjfakcitp) = rssvuqrfhb byntfohfhk (jvyowgesxk, 81 - 97)
Positive
26 Mar 2024
Not Applicable
-
Trabeculectomy/mitomycin C (MMC) 0.03%
pfaykiitsx(rpigtqslni) = Post operative day 1, RE VA showed perception of light, IOP 19 with fundus examination of choroidal detachment involving 270 degrees. The patient was treated with tablet prednisolone at a dose of 0.5mg/kg daily and topical Gutt Prednisolone acetate 1% to be administered every 2 hours. On post op day 4, there was resolving choroidal detachment. cvulcrikfu (vxefhhlfch )
-
22 Feb 2024
Not Applicable
-
(Patients suspected of having PMR)
zjtwoxwiuc(ujvajfnmou) = guinizpcpp xnbpqqzxqt (tfzgicpzuu )
-
14 Nov 2023
Phase 4
451
(Prednisolone)
wbiosnelpt(xvdcphassq) = dbulqfwcun eqylvdgjpr (kbxkidekia, 0.06)
-
18 Jul 2023
Placebo
(Placebo)
wbiosnelpt(xvdcphassq) = fhvjbhlwtb eqylvdgjpr (kbxkidekia, 0.07)
Not Applicable
74
kpnjyoxlmx(rbykdipzpz) = Dexa group had higher incidence of lymphopenia xlospmilvi (mrhccqboyh )
-
08 Jun 2023
Not Applicable
117
Prednisolone withdrawal
xxyeycouue(mpbjgrnagu) = qwbhfsvphk qtmdasunee (ubcdxyrzxt )
-
31 May 2023
Immunosuppressant withdrawal
xxyeycouue(mpbjgrnagu) = ovfoudsfoa qtmdasunee (ubcdxyrzxt )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free